Phosphoinositide 3-Kinase (PI3K) Inhibitors Market Size to Exceed $2.6 Billion by 2029 | Growth and Industry Trends
Claim your 30% discount on Global Market Reports with code ONLINE30. Limited time only.
How Has the Phosphoinositide 3-Kinase (PI3K) Inhibitors Market Grown from 2024 to 2025?
The market size of phosphoinositide 3-kinase (PI3K) inhibitors has been growing rapidly in recent years, and it is expected to expand from $1.38 billion in 2024 to $1.57 billion in 2025, with a compound annual growth rate (CAGR) of 13.7%. The growth experienced in the past is linked to factors such as an increase in cancer prevalence, advances in research related to targeted therapies, the approval of first-generation PI3K inhibitors by regulatory bodies, a surge in healthcare spending, and the proliferation of clinical trials for hematologic malignancies.
What Growth Rate Is Anticipated for the Phosphoinositide 3-Kinase (PI3K) Inhibitors Market in the Coming Years?
In the coming years, the market for phosphoinositide 3-kinase (PI3K) inhibitors is projected to experience significant growth, increasing to $2.61 billion by 2029 with a compound annual growth rate (CAGR) of 13.5%. Factors contributing to the predicted growth during this period include the rising appeal of combination therapies, the development of safer next-generation PI3K inhibitors, heightened investment in cancer research, applications beyond oncology, and the growth in the use of biomarkers for patient selection. Shifting towards dual and pan-isoform PI3K inhibitors, a growing preference for oral administration over intravenous methods, a rising focus on circumventing resistance mechanisms, the growing application of artificial intelligence in drug discovery, and the expanding role of PI3K inhibitors in immunotherapy combinations are some of the key trends during this forecast period.
Download The Free Sample Report Here:
https://www.thebusinessresearchcompany.com/sample.aspx?id=23474&type=smp
Who Are the Leading Companies in the Phosphoinositide 3-Kinase (PI3K) Inhibitors Market?
Major companies operating in the phosphoinositide 3-kinase (PI3K) inhibitors market are Pfizer Inc., F. Hoffmann-La Roche Ltd, Merck & Co., AbbVie Inc., Bayer AG, Sanofi SA, Bristol Myers Squibb, AstraZeneca PLC, Novartis AG, GlaxoSmithKline (GSK) Plc, Takeda Pharmaceutical Company Limited, Eli Lilly and Company, Gilead Sciences, Boehringer Ingelheim, Genentech Inc., Incyte Corporation, Exelixis, Kura Oncology, TG Therapeutics Inc., Verastem Oncology
What Are the Key Drivers of the Phosphoinositide 3-Kinase (PI3K) Inhibitors Market?
The escalating rates of cancer and autoimmune diseases are anticipated to fuel the expansion of the phosphoinositide 3-kinase (PI3K) inhibitors market in future. Diseases such as cancer are typified by uncontrolled multiplication and growth of cells, while autoimmune illnesses manifest when the body’s immunity system wrongly targets its own healthy tissues, provoking chronic inflammation and damage to tissues. The rise in these diseases can be traced back to heightened genetic vulnerability, culminating in an accumulation of genetic mutations and an imbalance in the body’s immune response. Phosphoinositide 3-kinase (PI3K) inhibitors become crucial in countering this rising trend by focusing on abnormal PI3K signaling, which plays a part in facilitating tumor expansion and immune disruption. Consequently, they provide medicinal benefits by adopting precision medicine approaches that augment treatment effectiveness and patient outcomes. For example, as per the National Cancer Institute, a US government agency, the tally of cancer survivors in the United States, which stood at 18.1 million in 2022, is foreseen to escalate to 22.5 million by 2032, with around 40.5% of the population potentially facing a cancer diagnosis in their lifetime. Hence, the rising incidence of cancer and autoimmune diseases serves as a catalyst for the growth of the Phosphoinositide 3-Kinase (PI3K) Inhibitors market.
Request For A Customized Report:
https://www.thebusinessresearchcompany.com/customise?id=23474&type=smp
What Are the Key Market Segments in the Phosphoinositide 3-Kinase (PI3K) Inhibitors Industry?
The phosphoinositide 3-kinase (PI3K) inhibitors market covered in this report is segmented –
1) By Type Of Inhibitor: Isoform Selective Inhibitors, Pan-Phosphoinositide 3-Kinase (PI3K) Inhibitors, Dual Phosphoinositide 3-Kinase (PI3K) Or Mechanistic Target Of Rapamycin (mTOR) Inhibitors, Novel Targeted Inhibitors
2) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies, Other Distribution Channel
3) By Application Areas: Cancer Treatment, Metabolic Disorders, Autoimmune Diseases, Neurological Disorders
4) By End User: Hospitals, Research Institutes, Pharmaceutical Companies, Contract Research Organizations (CROs)
Subsegments:
1) By Isoform Selective Inhibitors: Phosphoinositide 3-Kinase Alpha (PI3Kα), Phosphoinositide 3-Kinase Beta (PI3Kβ), Phosphoinositide 3-Kinase Delta (PI3Kδ), Phosphoinositide 3-Kinase Gamma (PI3Kγ)
2) By Pan-Phosphoinositide 3-Kinase (PI3K) Inhibitors: Class I Phosphoinositide 3-Kinase (PI3K), Non-Isoform Specific Phosphoinositide 3-Kinase (PI3K), Phosphoinositide 3-Kinase Kinase Domain
3) By Dual Phosphoinositide 3-Kinase (PI3K) Or Mechanistic Target of Rapamycin (mTOR) Inhibitors: Phosphoinositide 3-Kinase (PI3K) and Mechanistic Target of Rapamycin (mTOR) Inhibition, Adenosine Triphosphate-Competitive Dual Inhibitors, Allosteric Dual Inhibitors
4) By Novel Targeted Inhibitors: Next-Generation Phosphoinositide 3-Kinase, Targeting Mutant Phosphoinositide 3-Kinase Isoforms, Autophagy Modulators, Checkpoint Inhibitors, Combination Therapies
What Are the Latest Trends in the Phosphoinositide 3-Kinase (PI3K) Inhibitors Market?
Leading entities in the phosphoinositide 3-kinase (PI3K) inhibitors market are concentrated on creating unique solutions, including PI3K delta inhibitor treatments, to offer specific therapy options for ailments related to disarrayed phosphoinositide 3-kinase (PI3K) signaling. The PI3K delta inhibitor method, a targeted treatment, inhibits the PI3K delta enzyme crucial in immune cell signaling to diminish inflammation, autoimmune reactions, and select blood cancers. For instance, in March 2023, the US-based government regulatory body, the United States Food and Drug Administration (FDA), confirmed the approval of Joenja (leniolisib), marking it the first therapy for activated phosphoinositide 3-kinase delta syndrome (APDS) in patients aged 12 years and above. This authorization signified a substantial progress in targeted therapies by adopting a precision medicine tactic to address immune dysfunction resulting from genetic variations in the PIK3CD or PIK3R1 genes. The introduction of Joenja (leniolisib) not only broadens the clinical uses of phosphoinositide 3-kinase (PI3K) inhibitors beyond the scope of oncology, but it also emphasizes the increasing concentration on individualized treatments for rare immune-related disorders.
Access The Full Report Here:
What Are the Key Regional Markets in the Phosphoinositide 3-Kinase (PI3K) Inhibitors Industry?
North America was the largest region in the phosphoinositide 3-kinase (PI3K) inhibitors market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the phosphoinositide 3-kinase (PI3K) inhibitors market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Purchase The Full Report Today:
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=23474
This Report Delivers Insight On:
1. How big is the phosphoinositide 3-kinase (pi3k) inhibitors market, and how is it changing globally?
2. Who are the major companies in the phosphoinositide 3-kinase (pi3k) inhibitors market, and how are they performing?
3. What are the key opportunities and risks in the phosphoinositide 3-kinase (pi3k) inhibitors market right now?
4. Which products or customer segments are growing the most in the phosphoinositide 3-kinase (pi3k) inhibitors market?
5. What factors are helping or slowing down the growth of the phosphoinositide 3-kinase (pi3k) inhibitors market?
About The Business Research Company:
With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas +1 310-496-7795
Europe +44 7882 955267
Asia & Others +44 7882 955267 & +91 8897263534
Email us at info@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
